EGFR T790M/L858R-IN-5 (example 52) is a potent inhibitor of EGFR T790M/L858R with the inhibition percentage of 92.9% in the concerntration of 0.05 μM[1].

EGFR T790M/L858R-IN-6 (compound 53), a pyrimidine compound, is a potent EGFR T790M/L858R inhibitor. EGFR T790M/L858R-IN-6 shows 90.88% enzyme activity inhibition with 0.05 μM[1].

EGFR T790M/L858R-IN-7 (Compound 72) is a novel pyrimidine compound that inhibits the EGFR T790M and L858R mutation with a high efficacy (93% inhibition rate at 0.05 μM). EGFR T790M/L858R-IN-7 functions by specifically binding to the kinase domain of EGFR, thereby inhibiting its phosphorylation activity[1].

EGFR WT/T790M-IN-1 (Compound 16h) is a dual EGFR WT and EGFR T790 inhibitor. EGFR WT/T790M-IN-1 can arrest the cell cycle in G2/M phase and induce apoptosis. EGFR WT/T790M-IN-1 has anti-cancer activity[1].

EGFR WT/T790M-IN-2 (Compound 7c) is a EGFR T790M/WT inhibitor with IC50 values of 0.08 and 0.13 μM, respectively. EGFR WT/T790M-IN-2 induces apoptosis by blocking the G0-G1 phase (apoptosis). EGFR WT/T790M-IN-2 has antitumor activity[1].

EGFR-IN-101 (I-10) is a 2-phenylamino pyrimidine derivative. EGFR-IN-101 is a EGFR inhibitor. The IC50 values for EGFRL858R/T790M/C797S and Ba/F3-EGFRL858R/T790M/C797S are 33.26 and 106.4 nM, respectively. EGFR-IN-101 can be used IN the study of non-small cell lung cancer (NSCLC)[1].

EGFR-IN-102 (compound 6) is an oral active EGFR inhibitor with the IC50 of 2 nM, and can be used for study of non-small-cell lung cancer[1].

EGFR-IN-103 (compound 1) is a potent EGFR inhibitor with an IC50 of 6 nM for pEGFR[1].

EGFR-IN-104 (Compound A23) is an effective inhibitor of EGFR, with IC50 values of 0.33 μM and 0.133 μM against EGFRL858R/T790M and EGFRDel19/T790M/C797S, respectively. EGFR-IN-104 exhibits anticancer activity both in vitro and in vivo[1].

EGFR-IN-105 (Compound 5b) is an EGFR2 inhibitor with an IC50 value of 0.68 μM. EGFR-IN-105 exhibits anticancer activity and can induce apoptosis in cancer cells, which is used in the research of pancreatic cancer[1].

EGFR-IN-106 (compound 6) is a potentEGFR inhibitor with an IC50 value of 0.2396 µM. EGFR-IN-106 shows cytotoxic and anti-inflammatory activity[1]。

EGFR-IN-107 (compound 3r) is an orally active EGFR inhibitor with IC50 values of 0.4333 μM for EGFRWT and 0.0438 μM for EGFRL858R/T790M. EGFR-IN-107 has anti-proliferative activity and can inhibit the proliferation of H1975 cells and induce their apoptosis. EGFR-IN-107 can be used in cancer research[1].

EGFR-IN-108 (Compound 12) is a selective and covalent EGFR inhibitor (pIC50: 9.4)[1].

EGFR-IN-108 chloride (Compound Ru3S) is an EGFR inhibitor with an IC50 value of 5.8 nM for hEGFR. EGFR-IN-108 chloride induces apoptosis and has anti-proliferative activity against cancer cells. EGFR-IN-108 chloride also has anti-angiogenic effects[1].

EGFR-IN-109 (compound 4) is an EGFR inhibitor, with the IC50 values of 25.8 and 182.3 nM for EGFRWT and EGFRT790M, respectively. EGFR-IN-109 arrests the cancer cells’ growth at the G2/M phase and induces both early and late apoptosis. EGFR-IN-109 can be used in cancer research[1].

EGFR-IN-110 (Compound 6) is a covalent EGFR inhibitor, with pIC50 values of 9.2 and 8.7 for EGFR enzyme and EGFR cell, respectively. EGFR-IN-110 shows high EGFR potency and good kinase selectivity[1].

EGFR-PK/JNK-2-IN-1 (Compound 6c) is a dual inhibitor of EGFR-PK and JNK-2 with IC50s of 2.7 and 3.0 μM, respectively. EGFR-PK/JNK-2-IN-1 can induce apoptosis and induce cell cycle arrest at different cell phases. EGFR-PK/JNK-2-IN-1 can be used for the research of cancer[1].

EGFR-TK-IN-2 (compound 10b) is EGFR-TK inhibitor with the IC50 of 0.16 μM. EGFR-TK-IN-2 inhibits cell growth[1].

EGFR T790M/L858R/ACK1-IN-1 is a dual inhibitor of EGFR T790M/L858R and ACK1. IC50 values are 23 and 263 nM, respectively. EGFR T790M/L858R/ACK1-IN-1 can inhibit cell proliferation and has antitumor activity[1].

EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC50s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI50 of 601 nM[1].

EGFR/HER2-IN-12 (compound 14b) is a dual inhibitor of EGFR and HER2 with 81% and 51% inhibition at 10 μM. The toxicity of EGFR/HER2-IN-12 to cancer cells A431 and MDA-MB-361 was not significant[1].

Egg oil is a natural oil, which consists primarily of cholesterol, lecithin and glycerides of the fatty acids. Egg oil exhibits activity in regulating the gut microbial dysbiosis, alleviating obesity, insulin resistance and inflammation[1][2][3][4].

Egg oil is a natural oil, which consists primarily of cholesterol, lecithin and glycerides of the fatty acids. Egg oil exhibits activity in regulating the gut microbial dysbiosis, alleviating obesity, insulin resistance and inflammation[1][2][3][4].

EGLN1 Human Pre-designed siRNA Set A contains three designed siRNAs for EGLN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EGLN2 Human Pre-designed siRNA Set A contains three designed siRNAs for EGLN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EGLN3 Human Pre-designed siRNA Set A contains three designed siRNAs for EGLN3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EGR1 Human Pre-designed siRNA Set A contains three designed siRNAs for EGR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EGR2 Human Pre-designed siRNA Set A contains three designed siRNAs for EGR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EGR3 Human Pre-designed siRNA Set A contains three designed siRNAs for EGR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EGR4 Human Pre-designed siRNA Set A contains three designed siRNAs for EGR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHBP1 Human Pre-designed siRNA Set A contains three designed siRNAs for EHBP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHBP1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for EHBP1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHD1 Human Pre-designed siRNA Set A contains three designed siRNAs for EHD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHD2 Human Pre-designed siRNA Set A contains three designed siRNAs for EHD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHD3 Human Pre-designed siRNA Set A contains three designed siRNAs for EHD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHD4 Human Pre-designed siRNA Set A contains three designed siRNAs for EHD4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHF Human Pre-designed siRNA Set A contains three designed siRNAs for EHF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHHADH Human Pre-designed siRNA Set A contains three designed siRNAs for EHHADH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHMT1 Human Pre-designed siRNA Set A contains three designed siRNAs for EHMT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ehmt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ehmt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHMT1 Rat Pre-designed siRNA Set A contains three designed siRNAs for EHMT1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

EHMT2 Human Pre-designed siRNA Set A contains three designed siRNAs for EHMT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ehmt2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ehmt2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ehmt2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ehmt2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

EI24 Human Pre-designed siRNA Set A contains three designed siRNAs for EI24 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Eicosapentaenoyl serotonin (EPA-5-HT) is an N-acyl serotonin, a novel lipid present in the gut. Eicosapentaenoyl serotonin inhibits glucagon-like peptide-1 secretion and FAAH activity[1].

Eicosapentaenoyl-CoA triammonium (C20:5-CoA) is an unsaturated fatty acyl-CoA that can assist in the measurement of enzymatic activity of the TrWSD4 enzyme[1].